Literature DB >> 9739051

Functional activation of lymphocyte CD44 in peripheral blood is a marker of autoimmune disease activity.

P Estess1, H C DeGrendele, V Pascual, M H Siegelman.   

Abstract

Interactions between complementary receptors on leukocytes and endothelial cells play a central role in regulating extravasation from the blood and thereby affect both normal and pathologic inflammatory responses. CD44 on lymphocytes that has been "activated" to bind its principal ligand hyaluronate (HA) on endothelium can mediate the primary adhesion (rolling) of lymphocytes to vascular endothelial cells under conditions of physiologic shear stress, and this interaction is used for activated T cell extravasation into an inflamed site in vivo in mice (DeGrendele, H.C., P. Estess, L.J. Picker, and M.H. Siegelman. 1996. J. Exp. Med. 183:1119-1130. DeGrendele, H.D., P. Estess, and M.H. Siegelman. 1997. Science. 278:672-675. DeGrendele, H.C., P. Estess, and M.H. Siegelman. 1997. J. Immunol. 159: 2549-2553). Here, we have investigated the role of lymphocyte-borne-activated CD44 in the human and show that CD44-dependent primary adhesion is induced in human peripheral blood T cells through T cell receptor triggering. In addition, lymphocytes capable of CD44/HA-dependent rolling interactions can be found resident within inflamed tonsils. In analysis of peripheral bloods of patients from a pediatric rheumatology clinic, examining systemic lupus erythematosus, and a group of chronic arthropathies, expression of CD44-dependent primary adhesion strongly correlates with concurrent symptomatic disease, with 85% of samples from clinically active patients showing elevated levels of rolling activity (compared with only 4% of inactive patients). These rolling interactions are predominantly mediated by T cells. The results suggest that circulating T lymphocytes bearing activated CD44 are elevated under conditions of chronic inflammation and that these may represent a pathogenically important subpopulation of activated circulating cells that may provide a reliable marker for autoimmune or chronic inflammatory disease activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9739051      PMCID: PMC509100          DOI: 10.1172/JCI4235

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  66 in total

1.  Correlation of clonal T cell expansion with disease activity in systemic lupus erythematosus.

Authors:  T Mato; K Masuko; Y Misaki; N Hirose; K Ito; Y Takemoto; K Izawa; S Yamamori; T Kato; K Nishioka; K Yamamoto
Journal:  Int Immunol       Date:  1997-04       Impact factor: 4.823

2.  Correlation between conventional disease activity measures in juvenile chronic arthritis.

Authors:  A Ravelli; S Viola; N Ruperto; B Corsi; G Ballardini; A Martini
Journal:  Ann Rheum Dis       Date:  1997-03       Impact factor: 19.103

3.  Predominantly T-cell infiltrate in rheumatoid synovial membranes.

Authors:  J A Van Boxel; S A Paget
Journal:  N Engl J Med       Date:  1975-09-11       Impact factor: 91.245

Review 4.  Selectins and their ligands: current concepts and controversies.

Authors:  G S Kansas
Journal:  Blood       Date:  1996-11-01       Impact factor: 22.113

5.  A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis.

Authors:  J T Cassidy; J E Levinson; J C Bass; J Baum; E J Brewer; C W Fink; V Hanson; J C Jacobs; A T Masi; J G Schaller
Journal:  Arthritis Rheum       Date:  1986-02

6.  Preparation and properties of fluorescein-labelled hyaluronate.

Authors:  A N de Belder; K O Wik
Journal:  Carbohydr Res       Date:  1975-11       Impact factor: 2.104

7.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

8.  Kinetic analysis of Ia expression on T cells in patients with systemic lupus erythematosus.

Authors:  A Kitani; M Hara; T Hirose; K Norioka; W Hirose; M Kawagoe; H Nakamura
Journal:  J Clin Lab Immunol       Date:  1986-02

9.  Peripheral blood Ia-positive T cells. Increases in certain diseases and after immunization.

Authors:  D T Yu; R J Winchester; S M Fu; A Gibofsky; H S Ko; H G Kunkel
Journal:  J Exp Med       Date:  1980-01-01       Impact factor: 14.307

10.  Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4.

Authors:  D Wofsy; W E Seaman
Journal:  J Exp Med       Date:  1985-02-01       Impact factor: 14.307

View more
  23 in total

Review 1.  T cells as therapeutic targets in SLE.

Authors:  José C Crispín; Vasileios C Kyttaris; Cox Terhorst; George C Tsokos
Journal:  Nat Rev Rheumatol       Date:  2010-05-11       Impact factor: 20.543

2.  Induction of resistance to diabetes in non-obese diabetic mice by targeting CD44 with a specific monoclonal antibody.

Authors:  L Weiss; S Slavin; S Reich; P Cohen; S Shuster; R Stern; E Kaganovsky; E Okon; A M Rubinstein; D Naor
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

3.  The chemokine SDF-1 stimulates integrin-mediated arrest of CD34(+) cells on vascular endothelium under shear flow.

Authors:  A Peled; V Grabovsky; L Habler; J Sandbank; F Arenzana-Seisdedos; I Petit; H Ben-Hur; T Lapidot; R Alon
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

4.  Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activity.

Authors:  José C Crispín; Brendan T Keenan; Michele D Finnell; Bonnie L Bermas; Peter Schur; Elena Massarotti; Elizabeth W Karlson; Lisa M Fitzgerald; Sukran Ergin; Vasileios C Kyttaris; George C Tsokos; Karen H Costenbader
Journal:  Arthritis Rheum       Date:  2010-05

5.  Reduced expression of CD44 on monocytes and neutrophils in systemic lupus erythematosus: relations with apoptotic neutrophils and disease activity.

Authors:  A P Cairns; A D Crockard; J R McConnell; P A Courtney; A L Bell
Journal:  Ann Rheum Dis       Date:  2001-10       Impact factor: 19.103

6.  Suppressor activity and potency among regulatory T cells is discriminated by functionally active CD44.

Authors:  Mihail Firan; Sohita Dhillon; Pila Estess; Mark H Siegelman
Journal:  Blood       Date:  2005-09-22       Impact factor: 22.113

7.  Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment.

Authors:  S Brocke; C Piercy; L Steinman; I L Weissman; T Veromaa
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

8.  The CD44-initiated pathway of T-cell extravasation uses VLA-4 but not LFA-1 for firm adhesion.

Authors:  M H Siegelman; D Stanescu; P Estess
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

9.  Induction of interactions between CD44 and hyaluronic acid by a short exposure of human T cells to diverse pro-inflammatory mediators.

Authors:  A Ariel; O Lider; A Brill; L Cahalon; N Savion; D Varon; R Hershkoviz
Journal:  Immunology       Date:  2000-07       Impact factor: 7.397

10.  TNFalpha and IL-8 regulate the expression and function of CD44 variant proteins in human colon carcinoma cells.

Authors:  Michal Barshishat; Amiram Ariel; Liora Cahalon; Yehuda Chowers; Ofer Lider; Betty Schwartz
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.